Regis Coutant
Nazim Benchikh2
Agnès Linglart
Marc Nicolino- 1Department of Paediatric Endocrinology, University Hospital, Angers, France
- 2Rare Endocrine Disorders, Clinical Medical and Regulatory, Novo Nordisk, Paris, France
- 3AP-HP, Paris Saclay University, INSERM, Physiologie et Physiopathologie Endocriniennes, Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicetre, France
- 4Division of Pediatric Endocrinology and Metabolism, Lyon University Pediatric Hospital, Lyon, France
- 5Endocrinology and Bone Diseases Unit, Children’s Hospital, Toulouse University Hospital, University of Toulouse Paul Sabatier, INSERM-CNRS Unit 1291, Infinity Center, Toulouse, France
A Correction on
Determinants of adverse event occurrence in children with short stature born small for gestational age treated with growth hormone
By Coutant R, Benchikh N, Linglart A, Nicolino M and Salles J-P (2025) Front. Endocrinol. 16:1656966. doi: 10.3389/fendo.2025.1656966
The reference for “23. World Medical Association (2004)” was erroneously written as “23. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. (2004) 15:124–9. doi: 10.1001/jama.2013.281053”. It should be “23. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. (2004) 15(1):124–9”.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: growth hormone, small for gestational age, adverse events, serious adverse events, real-world data
Citation: Coutant R, Benchikh N, Linglart A, Nicolino M and Salles J-P (2025) Correction: Determinants of adverse event occurrence in children with short stature born small for gestational age treated with growth hormone. Front. Endocrinol. 16:1754016. doi: 10.3389/fendo.2025.1754016
Received: 25 November 2025; Accepted: 28 November 2025;
Published: 08 December 2025.
Edited and reviewed by:
Michael Freemark, Duke University, United StatesCopyright © 2025 Coutant, Benchikh, Linglart, Nicolino and Salles. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Regis Coutant, cmVjb3V0YW50QGNodS1hbmdlcnMuZnI=
†ORCID: Regis Coutant, orcid.org/0000-0002-6332-4243
Agnès Linglart, orcid.org/0000-0003-3455-002X
Marc Nicolino, orcid.org/0000-0001-5395-2249
Jean-Pierre Salles, orcid.org/0000-0002-0941-8951